Lines by EBV Nuclear Antigen-Specific CD4 the Recognition of EBV-Transformed B Cell A Role for Intercellular Antigen Transfer in

The CD4 (cid:1) T cell response to EBV may have an important role in controlling virus-driven B lymphoproliferation because CD4 (cid:1) T cell clones to a subset of EBV nuclear Ag (EBNA) epitopes can directly recognize virus-transformed lymphoblastoid cell lines (LCLs) in vitro and inhibit their growth. In this study, we used a panel of EBNA1, 2, 3A, and 3C-specific CD4 (cid:1) T cell clones to study the route whereby endogenously expressed EBNAs access the HLA class II-presentation pathway. Two sets of results spoke against a direct route of intracellular access. First, none of the clones recognized cognate Ag overexpressed in cells from vaccinia vectors but did recognize Ag fused to an endo/lysosomal targeting sequence. Second, focusing on clones with the strongest LCL recognition that were specific for EBNA2- and EBNA3C-derived epitopes LCL recognition was unaffected by inhibiting autophagy, a postulated route for intracellular Ag delivery into the HLA class II pathway in LCL cells. Subsequently, using these same epitope-specific clones, we found that Ag-negative cells with the appropriate HLA-restricting allele could be efficiently sensitized to CD4 (cid:1) T cell recognition by cocultivation with Ag-positive donor lines or by exposure to donor line-conditioned culture medium. Sensitization was mediated by a high m.w. antigenic species and required active Ag processing by recipient cells. We infer that intercellular Ag transfer plays a major role in the presentation of EBNA-derived CD4 epitopes by latently infected target cells. The Journal of Immunology, 2006, 177: 3746–3756.

[1]  A. Moosmann,et al.  Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins , 2006, The Journal of experimental medicine.

[2]  M. Bonneville,et al.  Long-Term MHC Class II Presentation of the EBV Lytic Protein BHRF1 by EBV Latently Infected B Cells following Capture of BHRF1 Antigen1 , 2005, The Journal of Immunology.

[3]  H. Rammensee,et al.  Autophagy promotes MHC class II presentation of peptides from intracellular source proteins , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Delu Zhou,et al.  Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. , 2005, Immunity.

[5]  A. Rickinson,et al.  CD4+ T-Cell Responses to Epstein-Barr Virus (EBV) Latent-Cycle Antigens and the Recognition of EBV-Transformed Lymphoblastoid Cell Lines , 2005, Journal of Virology.

[6]  A. Rickinson,et al.  CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells , 2005, The Journal of experimental medicine.

[7]  T. Tuschl,et al.  Endogenous MHC Class II Processing of a Viral Nuclear Antigen After Autophagy , 2005, Science.

[8]  L. Young,et al.  Epstein–Barr virus: 40 years on , 2004, Nature Reviews Cancer.

[9]  W. Hammerschmidt,et al.  Epstein‐Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells , 2004, European journal of immunology.

[10]  B. Rocha,et al.  Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. , 2004, Current opinion in immunology.

[11]  M. Bonneville,et al.  Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. , 2004, Blood.

[12]  E. Jaffee,et al.  Major histocompatibility complex class II‐restricted presentation of a cytosolic antigen by autophagy , 2003, European journal of immunology.

[13]  H. Heslop,et al.  Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. , 2002, Cancer research.

[14]  A. Rickinson,et al.  Epstein–Barr virus–associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2 , 2002, Nature Medicine.

[15]  Hiroya Kobayashi,et al.  Inhibition of EBV-Induced Lymphoproliferation by CD4+ T Cells Specific for an MHC Class II Promiscuous Epitope1 , 2002, The Journal of Immunology.

[16]  S. Stevanović,et al.  Epstein-Barr Nuclear Antigen 1-Specific CD4+ Th1 Cells Kill Burkitt’s Lymphoma Cells1 , 2002, The Journal of Immunology.

[17]  D. Crawford,et al.  Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. , 2001, Transplantation.

[18]  E. Bloemena,et al.  Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses , 2001, Journal of Virology.

[19]  A. Rudensky,et al.  Efficient Presentation of Both Cytosolic and Endogenous Transmembrane Protein Antigens on MHC Class II Is Dependent on Cytoplasmic Proteolysis1 , 2001, The Journal of Immunology.

[20]  A. Rickinson,et al.  Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. , 2001, Cancer research.

[21]  S. Riddell,et al.  Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+ and CD8+ T Cells1 , 2001, The Journal of Immunology.

[22]  W. Hammerschmidt,et al.  The Epstein–Barr virus lytic program is controlled by the co‐operative functions of two transactivators , 2000, The EMBO journal.

[23]  R. Steinman,et al.  Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1 , 2000, The Journal of experimental medicine.

[24]  J. Elliott,et al.  Cytoplasmic Processing Is a Prerequisite for Presentation of an Endogenous Antigen by Major Histocompatibility Complex Class II Proteins , 2000, The Journal of experimental medicine.

[25]  R. Karr,et al.  A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes. , 2000, International immunology.

[26]  Richard E. Slaughter,et al.  Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Eggermont,et al.  Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.

[28]  M. Nishioka,et al.  Efficient Class II Major Histocompatibility Complex Presentation of Endogenously Synthesized Hepatitis C Virus Core Protein by Epstein-Barr Virus-Transformed B-Lymphoblastoid Cell Lines to CD4+ T Cells , 1998, Journal of Virology.

[29]  A. Alcamí,et al.  Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. , 1998, The Journal of general virology.

[30]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[31]  L. Frappier,et al.  Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. , 1997, Immunity.

[32]  M. Jackson,et al.  Major Histocompatibility Complex Class II-dependent Unfolding, Transport, and Degradation of Endogenous Proteins* , 1997, The Journal of Biological Chemistry.

[33]  S. Burrows,et al.  Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. , 1997, International immunology.

[34]  P. Cresswell,et al.  Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. , 1997, Journal of immunology.

[35]  A. Rickinson,et al.  Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. , 1997, Journal of immunology.

[36]  Eric O Long,et al.  Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. Melief,et al.  B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.

[38]  S. Burrows,et al.  Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. , 1995, Virology.

[39]  Kathleen R. Cho,et al.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Tonegawa,et al.  Presentation of endogenous viral proteins in association with major histocompatibility complex class II: On the role of intracellular compartmentalization, invariant chain and the TAP transporter system , 1995, European journal of immunology.

[41]  S. Diment,et al.  Processing of a viral glycoprotein in the endoplasmic reticulum for class II presentation , 1995, European journal of immunology.

[42]  J. Trowsdale,et al.  Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein‐Barr virus latent membrane protein‐1: coordinate up‐regulation of peptide transporters and HLA‐class I antigen expression , 1995, European journal of immunology.

[43]  S. Burrows,et al.  Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. , 1994, The Journal of general virology.

[44]  S. Burrows,et al.  Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. , 1994, International immunology.

[45]  Eric O Long,et al.  Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC. , 1993, Journal of immunology.

[46]  A. Rickinson,et al.  Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide , 1993, The Journal of experimental medicine.

[47]  M. Masucci,et al.  Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4 , 1993, Journal of virology.

[48]  E. Kieff,et al.  Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies , 1992, The Journal of experimental medicine.

[49]  E. Kieff,et al.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development , 1992, The Journal of experimental medicine.

[50]  Eric O Long,et al.  Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells , 1992, Nature.

[51]  S. Weiss,et al.  MHC class II—Restricted presentation of intracellular antigen , 1991, Cell.

[52]  Eric O Long,et al.  An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells , 1990, The Journal of experimental medicine.

[53]  R. Siliciano,et al.  Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition , 1990, The Journal of experimental medicine.

[54]  I. Berkower,et al.  Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen , 1988, The Journal of experimental medicine.

[55]  P. Seglen,et al.  3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[56]  W. Joklik The purification fo four strains of poxvirus. , 1962, Virology.